

Author's response to reviews

Title: Is untargeted educational outreach visiting delivered by Pharmaceutical Advisers effective in primary care? A pragmatic randomized controlled trial.

Authors:

Martin P Eccles (martin.eccles@ncl.ac.uk)

Ian N Steen (nick.steen@ncl.ac.uk)

Paula M Whitty (p.m.whitty@ncl.ac.uk)

Lesley Hall (lesley.hall@ncl.ac.uk)

Version: 3 **Date:** 4 May 2007

Author's response to reviews: see over

Institute for Health and Society
Newcastle University
21 Claremont Place
Newcastle upon Tyne
NE2 4AA

4th May 2007

Dr Brian Mittman,
The Editor,
Implementation Science,
<http://www.implementationscience.com>

Dear Brian,

Is untargeted educational outreach visiting delivered by Pharmaceutical Advisers effective in primary care? A pragmatic randomized controlled trial.

Thank you for your correspondence about this paper. We were delighted to hear that the paper will be accepted.

Further to your comments, we have (1) added a sentence to the power calculation within the methods, as follows:

‘This equates approximately to a mean difference per ASTRO PU of 0.5 items of Lofepamine, 2.4 items of other TCAs, 1.5 items of SSRIs and 0.05 items of MAOIs.’

However, so as not to disturb the current flow of the paper (where the outcome measures are explained in the ‘Analysis’ section), we have moved the original location of the power calculation from the ‘Study design’ section to a new section titled ‘Power calculation’. This now follows the ‘Analysis’ section. The original text has been replaced in the ‘Study Design’ section by:

‘(See ‘Power Calculation’ for more detail).’

The new ‘Power Calculation’ section reads as:

‘Power calculation

As reported earlier, the total number of available general practices (73) was pre-determined. With 36 practices randomized to intervention and 37 to control, we determined that we had 80 per cent power to detect an effect size of 0.66 standard deviations in our outcome measures assuming a type 1 error rate of 0.05. This equates approximately to a mean difference per ASTRO PU of 0.5 items of Lofepamine, 2.4 items of other TCAs, 1.5 items of SSRIs and 0.05 items of MAOIs.’

(2) We have added a disclaimer statement to the ‘Conflicts of Interest’ section, relating to Martin Eccles’s role as co-editor, as follows:

‘Martin Eccles is Co-Editor in Chief of Implementation Science. All editorial decisions on this article were made by Co-Editor in Chief Brian Mittman.’

I hope that these amendments are satisfactory to you, and that the acceptance process can now proceed. However, please do not hesitate to contact me if you need anything else.

With best wishes.
Yours sincerely,

Dr Paula Whitty
Senior Lecturer in Medical Care Epidemiology
Institute of Health and Society
Newcastle University
Email: p.m.whitty@ncl.ac.uk